➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Colorcon
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson

Last Updated: June 6, 2020

DrugPatentWatch Database Preview

XTORO Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Xtoro patents expire, and what generic alternatives are available?

Xtoro is a drug marketed by Merlion Pharms Gmbh and is included in one NDA. There are three patents protecting this drug.

This drug has forty patent family members in eighteen countries.

The generic ingredient in XTORO is finafloxacin. Additional details are available on the finafloxacin profile page.

US ANDA Litigation and Generic Entry Outlook for Xtoro

Xtoro was eligible for patent challenges on December 17, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 2, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for XTORO
International Patents:40
US Patents:3
Applicants:1
NDAs:1
Bulk Api Vendors: 26
Patent Applications: 13
DailyMed Link:XTORO at DailyMed
Drug patent expirations by year for XTORO
Generic Entry Opportunity Date for XTORO
Generic Entry Date for XTORO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SUSPENSION/DROPS;OTIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for XTORO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merlion Pharms Gmbh XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 DISCN Yes No   Start Trial   Start Trial   Start Trial
Merlion Pharms Gmbh XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 DISCN Yes No   Start Trial   Start Trial   Start Trial
Merlion Pharms Gmbh XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Merlion Pharms Gmbh XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Colorcon
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.